After nearly 40 years usage, 5-fluorouracil (5-FU) is still widely used against a variety of solid
tumors, especially head and neck and colorectal cancers [1, 2]. Recent advances in basic …

PURPOSE: Patients with genetic fluorouracil (5-FU) catabolic deficiencies are at high risk for
severe toxicity. To predict 5-FU catabolic deficiencies and toxic side effects, we conducted a …

Abstract BACKGROUND A phase II prospective trial was carried out to study the concept of 5‐
fluorouracil (5‐FU) dose‐intensity in patients with advanced colorectal cancer. Forty patients …

PURPOSE A relationship between fluorouracil (5-FU) dose and response has been
previously shown in advanced colorectal cancer. In a previous study with 5-FU stepwise …

Twenty-nine previously untreated patients with head and neck carcinoma received a total of
63 cycles of an initial chemotherapy protocol combining cis-platinum (100 mg/m 2 on day 1) …

It is obvious that there are great problems with pharmacokinetic individualisation of anti-
cancer therapy. The strong relationship between dose intensity (total dose/unit time) and …

The influence of oxaliplatin (OXA) on 5-fluorouracil (5-FU) plasma clearance was
investigated. Patients and methods: A group of 29 patients with advanced colorectal cancer …

Ob‰ írná monografie vûnovaná problematice kolorektálního karcinomu byla pfiipravena za
spolupráce 77 odborníkÛ. Obsah je rozdûlen do devíti ãástí s 67 kapitolami. Nejprve je …

Chemotherapeutic agents are generally characterized by a large inter‐individual
pharmacokinetic variability. The balance of efficacy and toxicity is critical and the imbalance …

The study described herein was conducted to analyze the relationship between tumor
exposure to 5-FU and clinical response. Six patients were placed on continuous 5-day …